Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,366.45",
    "chg": -18.55,
    "chgp": "-1.34%",
    "dir": -1,
    "prev_price": "1,385.00",
    "mcapval": "110,389.82 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "Sep 22, 11:15 AM",
    "curr_time": "11:16 AM",
    "last_traded_at": "Sep 22, 11:15 AM IST",
    "bse_nse_vol": "1.14 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 22, 2026",
    "traded_date_str": "2026 09 22",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cipla Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-technical-momentum-shifts-amid-mixed-market-signals-4200320",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CiplaLtd_technicaldot_4200320.png",
        "date": "2026-09-22 08:04:16",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.99%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes, placing Cipla’s price action in the context of broader market movements and sectoral trends."
      },
      {
        "title": "P/E at 30.96 vs Industry's 37.18: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4199304",
        "imagepath": "",
        "date": "2026-09-21 09:20:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership for Cipla Ltd</strong></p>\n                <p>Cipla Ltd’s inclusion in the Nifty 50 index is a testament to its market capitalisation, liquidity, and sectoral influence. With a market cap of ₹1,12,841.67 crores, Cipla stands as a large-cap heavyweight within the Pharmaceuticals & Biotechnology sector. Membership in this benchmark index not only enhances the stock’s visibility among institutional investors but also ensures its inclusion in numerous passive investment funds and ETFs tracking the Nifty 50. This status typically supports liquidity and can provide a valuation premium relative to non-index stocks.</p>\n                <p>However, maintaining this position demands consistent financial performance and positive market sentiment, facto..."
      },
      {
        "title": "Cipla Ltd. Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-4196644",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CiplaLtd_valuationdot_4196644.png",
        "date": "2026-09-18 08:00:38",
        "description": "Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. This change comes amid a backdrop of mixed returns relative to the broader market and peers, prompting a reassessment of its price attractiveness based on key metrics such as P/E and P/BV ratios."
      },
      {
        "title": "P/E at 30.69 vs Industry's 36.44: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-4195871",
        "imagepath": "",
        "date": "2026-09-17 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 30.69, which is approximately 15.8% below the Pharmaceuticals & Biotechnology industry's average P/E of 36.44. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives higher risks relative to its peers. Given the sector's elevated valuation, this gap could imply that investors are factoring in challenges specific to <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> — <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla</a> — <a class=\"..."
      },
      {
        "title": "P/E at 30.72 vs Industry's 36.52: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-sector-dynamics-4194608",
        "imagepath": "",
        "date": "2026-09-16 09:20:38",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 30.72, which is approximately 16% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount is significant given the sector’s generally elevated valuations, reflecting investor caution or concerns specific to the company’s earnings outlook. The valuation gap may also imply that the market is pricing in slower growth or margin pressures relative to peers. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s market capitalisation stands at ₹1,09,993.97 crores, firmly placing it in the large-cap category wit..."
      },
      {
        "title": "P/E at 30.81 vs Industry's 37.05: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-sector-dynamics-4192873",
        "imagepath": "",
        "date": "2026-09-15 09:20:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> stands at 30.81, which is approximately 16.8% lower than the Pharmaceuticals &amp; Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risks relative to its peers. Given the sector’s elevated valuation, the stock’s relative affordability could be signalling underlying concerns or a divergence in growth expectations. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s market capitalisation of ₹1,09,392.11 crores places i..."
      },
      {
        "title": "Cipla Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-sell-by-marketsmojo-4192509",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CiplaLtd_mojoScore_4192509.png",
        "date": "2026-09-14 10:10:17",
        "description": "Cipla Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 02 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Cipla Ltd. Valuation Shifts to Fair Amidst Sector Comparisons and Market Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-valuation-shifts-to-fair-amidst-sector-comparisons-and-market-trends-4189674",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CiplaLtd_valuationdot_4189674.png",
        "date": "2026-09-11 08:00:24",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change, accompanied by a downgrade in its Mojo Grade from Hold to Sell as of 2 September 2026, reflects evolving market perceptions amid rising price-to-earnings and price-to-book ratios. This article delves into Cipla’s current valuation metrics, compares them with industry peers, and analyses the implications for investors seeking value in the large-cap pharmaceutical space."
      },
      {
        "title": "P/E at 30.88 vs Industry's 37.21: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-4188798",
        "imagepath": "",
        "date": "2026-09-10 09:20:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> at 30.88 stands well below the sector average of 37.21, signalling a valuation discount of nearly 17%. This gap suggests that the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. The Pharmaceuticals &amp; Biotechnology sector often commands premium valuations due to its defensive characteristics and growth potential, but <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> appears to be an exception. This divergence raises the question — <a href=\"https://www.marketsmojo.com/stocks-analysis/..."
      }
    ],
    "total": 1204,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "caption": "Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "18-Sep-2026",
      "details": "Please find enclosed disclosure on ESG Rating.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "03-Sep-2026",
      "details": "Please find enclosed press release titled Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US",
      "source": "BSE"
    },
    {
      "caption": "Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company",
      "datetime": "03-Sep-2026",
      "details": "Please find enclosed disclosure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 05 Jun 26",
          "dt": "2026-06-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cipla Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-09-22 08:04:16

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.99%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes, placing Cipla’s price action in the context of broader market movements and sectoral trends.

Read full news article

P/E at 30.96 vs Industry's 37.18: What the Data Shows for Cipla Ltd.

2026-09-21 09:20:42

Significance of Nifty 50 Membership for Cipla Ltd

Cipla Ltd’s inclusion in the Nifty 50 index is a testament to its market capitalisation, liquidity, and sectoral influence. With a market cap of ₹1,12,841.67 crores, Cipla stands as a large-cap heavyweight within the Pharmaceuticals & Biotechnology sector. Membership in this benchmark index not only enhances the stock’s visibility among institutional investors but also ensures its inclusion in numerous passive investment funds and ETFs tracking the Nifty 50. This status typically supports liquidity and can provide a valuation premium relative to non-index stocks.

However, maintaining this position demands consistent financial performance and positive market sentiment, facto...

Read full news article

Cipla Ltd. Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-09-18 08:00:38

Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to attractive territory. This change comes amid a backdrop of mixed returns relative to the broader market and peers, prompting a reassessment of its price attractiveness based on key metrics such as P/E and P/BV ratios.

Read full news article

P/E at 30.69 vs Industry's 36.44: What the Data Shows for Cipla Ltd.

2026-09-17 09:20:50

Valuation Picture: Discount to Industry P/E

Cipla Ltd. trades at a P/E multiple of 30.69, which is approximately 15.8% below the Pharmaceuticals & Biotechnology industry's average P/E of 36.44. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives higher risks relative to its peers. Given the sector's elevated valuation, this gap could imply that investors are factoring in challenges specific to Cipla Ltd. — Cipla — Read full news article

P/E at 30.72 vs Industry's 36.52: What the Data Shows for Cipla Ltd.

2026-09-16 09:20:38

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E multiple of 30.72, which is approximately 16% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount is significant given the sector’s generally elevated valuations, reflecting investor caution or concerns specific to the company’s earnings outlook. The valuation gap may also imply that the market is pricing in slower growth or margin pressures relative to peers. Cipla Ltd.’s market capitalisation stands at ₹1,09,993.97 crores, firmly placing it in the large-cap category wit...

Read full news article

P/E at 30.81 vs Industry's 37.05: What the Data Shows for Cipla Ltd.

2026-09-15 09:20:42

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Cipla Ltd. stands at 30.81, which is approximately 16.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risks relative to its peers. Given the sector’s elevated valuation, the stock’s relative affordability could be signalling underlying concerns or a divergence in growth expectations. Cipla Ltd.’s market capitalisation of ₹1,09,392.11 crores places i...

Read full news article

Cipla Ltd. is Rated Sell by MarketsMOJO

2026-09-14 10:10:17

Cipla Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 02 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Cipla Ltd. Valuation Shifts to Fair Amidst Sector Comparisons and Market Trends

2026-09-11 08:00:24

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change, accompanied by a downgrade in its Mojo Grade from Hold to Sell as of 2 September 2026, reflects evolving market perceptions amid rising price-to-earnings and price-to-book ratios. This article delves into Cipla’s current valuation metrics, compares them with industry peers, and analyses the implications for investors seeking value in the large-cap pharmaceutical space.

Read full news article

P/E at 30.88 vs Industry's 37.21: What the Data Shows for Cipla Ltd.

2026-09-10 09:20:36

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Cipla Ltd. at 30.88 stands well below the sector average of 37.21, signalling a valuation discount of nearly 17%. This gap suggests that the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its defensive characteristics and growth potential, but Cipla Ltd. appears to be an exception. This divergence raises the question — Read full news article

View All News